# Salesforce, Inc.: financial statements, quarterly

CRM · NYSE · CIK 1108524 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/crm.md) · [Financials](/companies/crm/financials.md) · [Filings](/companies/crm/filings.md) · [Insiders](/companies/crm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [8.7](/filings/0001108524-24-000034.md) | [9.3 d](/filings/0001108524-26-000060.md) | [9.1](/filings/0001108524-25-000030.md) | [9.3](/filings/0001108524-25-000088.md) | [9.4](/filings/0001108524-25-000238.md) | [10.0 d](/filings/0001108524-26-000060.md) | [9.8](/filings/0001108524-26-000127.md) | [10.2](/filings/0001108524-26-000190.md) | [10.3](/filings/0001108524-25-000238.md) | [11.2 d](/filings/0001108524-26-000060.md) | [11.1](/filings/0001108524-26-000127.md) | [11.3](/filings/0001108524-26-000190.md) |
| Cost of revenue | $bn | [2.2](/filings/0001108524-24-000034.md) | [2.1 d](/filings/0001108524-26-000060.md) | [2.2](/filings/0001108524-25-000030.md) | [2.2](/filings/0001108524-25-000088.md) | [2.1](/filings/0001108524-25-000238.md) | [2.2 d](/filings/0001108524-26-000060.md) | [2.3](/filings/0001108524-26-000127.md) | [2.2](/filings/0001108524-26-000190.md) | [2.3](/filings/0001108524-25-000238.md) | [2.5 d](/filings/0001108524-26-000060.md) | [2.6](/filings/0001108524-26-000127.md) | [2.6](/filings/0001108524-26-000190.md) |
| Gross profit | $bn | [6.6](/filings/0001108524-24-000034.md) | [7.1 d](/filings/0001108524-26-000060.md) | [7.0](/filings/0001108524-25-000030.md) | [7.2](/filings/0001108524-25-000088.md) | [7.3](/filings/0001108524-25-000238.md) | [7.8 d](/filings/0001108524-26-000060.md) | [7.6](/filings/0001108524-26-000127.md) | [8.0](/filings/0001108524-26-000190.md) | [8.0](/filings/0001108524-25-000238.md) | [8.7 d](/filings/0001108524-26-000060.md) | [8.6](/filings/0001108524-26-000127.md) | [8.7](/filings/0001108524-26-000190.md) |
| Research and development | $bn | [1.2](/filings/0001108524-24-000034.md) | [1.3 d](/filings/0001108524-26-000060.md) | [1.4](/filings/0001108524-25-000030.md) | [1.3](/filings/0001108524-25-000088.md) | [1.4](/filings/0001108524-25-000238.md) | [1.4 d](/filings/0001108524-26-000060.md) | [1.5](/filings/0001108524-26-000127.md) | [1.5](/filings/0001108524-26-000190.md) | [1.4](/filings/0001108524-25-000238.md) | [1.6 d](/filings/0001108524-26-000060.md) | [1.6](/filings/0001108524-26-000127.md) | [1.7](/filings/0001108524-26-000190.md) |
| Operating income | $bn | [1.5](/filings/0001108524-24-000034.md) | [1.6 d](/filings/0001108524-26-000060.md) | [1.7](/filings/0001108524-25-000030.md) | [1.8](/filings/0001108524-25-000088.md) | [1.9](/filings/0001108524-25-000238.md) | [1.8 d](/filings/0001108524-26-000060.md) | [1.9](/filings/0001108524-26-000127.md) | [2.3](/filings/0001108524-26-000190.md) | [2.2](/filings/0001108524-25-000238.md) | [1.9 d](/filings/0001108524-26-000060.md) | [2.3](/filings/0001108524-26-000127.md) | [2.3](/filings/0001108524-26-000190.md) |
| Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001108524-26-000127.md) | [0.1](/filings/0001108524-26-000190.md) | not reported | not reported | [0.3](/filings/0001108524-26-000127.md) | [0.5](/filings/0001108524-26-000190.md) |
| Income tax | $bn | [0.3](/filings/0001108524-24-000034.md) | [0.2 d](/filings/0001108524-26-000060.md) | [0.3](/filings/0001108524-25-000030.md) | [0.4](/filings/0001108524-25-000088.md) | [0.2](/filings/0001108524-25-000238.md) | [0.3 d](/filings/0001108524-26-000060.md) | [0.4](/filings/0001108524-26-000127.md) | [0.5](/filings/0001108524-26-000190.md) | [0.4](/filings/0001108524-25-000238.md) | [0.7 d](/filings/0001108524-26-000060.md) | [0.6](/filings/0001108524-26-000127.md) | [1.0](/filings/0001108524-26-000190.md) |
| Net income | $bn | [1.2](/filings/0001108524-24-000034.md) | [1.4 d](/filings/0001108524-26-000060.md) | [1.5](/filings/0001108524-25-000238.md) | [1.4](/filings/0001108524-25-000238.md) | [1.5](/filings/0001108524-25-000238.md) | [1.7 d](/filings/0001108524-26-000060.md) | [1.5](/filings/0001108524-26-000190.md) | [1.9](/filings/0001108524-26-000190.md) | [2.1](/filings/0001108524-25-000238.md) | [1.9 d](/filings/0001108524-26-000060.md) | [2.1](/filings/0001108524-26-000190.md) | [3.5](/filings/0001108524-26-000190.md) |
| Diluted EPS | $ per share | [1.25](/filings/0001108524-24-000034.md) | not reported | [1.56](/filings/0001108524-25-000030.md) | [1.47](/filings/0001108524-25-000088.md) | [1.58](/filings/0001108524-25-000238.md) | not reported | [1.59](/filings/0001108524-26-000127.md) | [1.96](/filings/0001108524-26-000190.md) | [2.19](/filings/0001108524-25-000238.md) | not reported | [2.42](/filings/0001108524-26-000127.md) | [4.29](/filings/0001108524-26-000190.md) |
| Basic EPS | $ per share | [1.26](/filings/0001108524-24-000034.md) | not reported | [1.58](/filings/0001108524-25-000030.md) | [1.48](/filings/0001108524-25-000088.md) | [1.60](/filings/0001108524-25-000238.md) | not reported | [1.61](/filings/0001108524-26-000127.md) | [1.97](/filings/0001108524-26-000190.md) | [2.20](/filings/0001108524-25-000238.md) | not reported | [2.43](/filings/0001108524-26-000127.md) | [4.30](/filings/0001108524-26-000190.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [6.5](/filings/0001108524-23-000048.md) | [8.5](/filings/0001108524-25-000006.md) | [10.0](/filings/0001108524-24-000009.md) | [7.7](/filings/0001108524-24-000022.md) | [8.0](/filings/0001108524-24-000034.md) | [8.8](/filings/0001108524-26-000060.md) | [10.9](/filings/0001108524-25-000030.md) | [10.4](/filings/0001108524-25-000088.md) | [9.0](/filings/0001108524-25-000238.md) | [7.3](/filings/0001108524-26-000190.md) | [8.9](/filings/0001108524-26-000127.md) | [8.3](/filings/0001108524-26-000190.md) |
| Current assets | $bn | [20.2](/filings/0001108524-23-000048.md) | [29.1](/filings/0001108524-25-000006.md) | [25.6](/filings/0001108524-24-000009.md) | [21.9](/filings/0001108524-24-000022.md) | [21.4](/filings/0001108524-24-000034.md) | [29.7](/filings/0001108524-26-000060.md) | [25.9](/filings/0001108524-25-000030.md) | [25.3](/filings/0001108524-25-000088.md) | [21.1](/filings/0001108524-25-000238.md) | [28.2](/filings/0001108524-26-000190.md) | [21.6](/filings/0001108524-26-000127.md) | [22.1](/filings/0001108524-26-000190.md) |
| Total assets | $bn | [91.0](/filings/0001108524-23-000048.md) | [99.8](/filings/0001108524-25-000006.md) | [96.2](/filings/0001108524-24-000009.md) | [92.2](/filings/0001108524-24-000022.md) | [91.4](/filings/0001108524-24-000034.md) | [103](/filings/0001108524-26-000060.md) | [98.6](/filings/0001108524-25-000030.md) | [97.6](/filings/0001108524-25-000088.md) | [95.1](/filings/0001108524-25-000238.md) | [112](/filings/0001108524-26-000190.md) | [107](/filings/0001108524-26-000127.md) | [110](/filings/0001108524-26-000190.md) |
| Current liabilities | $bn | [19.4](/filings/0001108524-23-000048.md) | [26.6](/filings/0001108524-25-000006.md) | [23.1](/filings/0001108524-24-000009.md) | [21.0](/filings/0001108524-24-000022.md) | [19.4](/filings/0001108524-24-000034.md) | [28.0](/filings/0001108524-26-000060.md) | [24.2](/filings/0001108524-25-000030.md) | [22.5](/filings/0001108524-25-000088.md) | [21.4](/filings/0001108524-25-000238.md) | [37.1](/filings/0001108524-26-000190.md) | [27.5](/filings/0001108524-26-000127.md) | [26.3](/filings/0001108524-26-000190.md) |
| Total liabilities | $bn | [32.9](/filings/0001108524-23-000048.md) | [40.2](/filings/0001108524-25-000006.md) | [36.5](/filings/0001108524-24-000009.md) | [34.5](/filings/0001108524-24-000022.md) | [32.9](/filings/0001108524-24-000034.md) | [41.8](/filings/0001108524-26-000060.md) | [37.9](/filings/0001108524-25-000030.md) | [36.2](/filings/0001108524-25-000088.md) | [35.1](/filings/0001108524-25-000238.md) | [53.2](/filings/0001108524-26-000190.md) | [72.4](/filings/0001108524-26-000127.md) | [71.2](/filings/0001108524-26-000190.md) |
| Long-term debt | $bn | [8.4](/filings/0001108524-23-000048.md) | [8.4](/filings/0001108524-25-000006.md) | [8.4](/filings/0001108524-24-000009.md) | [8.4](/filings/0001108524-24-000022.md) | [8.4](/filings/0001108524-24-000034.md) | [8.4](/filings/0001108524-26-000060.md) | [8.4](/filings/0001108524-25-000030.md) | [8.4](/filings/0001108524-25-000088.md) | [8.4](/filings/0001108524-25-000238.md) | [10.4](/filings/0001108524-26-000190.md) | [39.3](/filings/0001108524-26-000127.md) | [39.3](/filings/0001108524-26-000190.md) |
| Current portion of debt | $bn | [1.0](/filings/0001108524-23-000048.md) | [1.0](/filings/0001108524-25-000006.md) | [1.0](/filings/0001108524-24-000009.md) | [0.0](/filings/0001108524-24-000022.md) | [0.0](/filings/0001108524-24-000034.md) | [0.0](/filings/0001108524-26-000060.md) | [0.0](/filings/0001108524-25-000030.md) | [0.0](/filings/0001108524-25-000088.md) | [0.0](/filings/0001108524-25-000238.md) | [4.0](/filings/0001108524-26-000190.md) | [0.0](/filings/0001108524-26-000127.md) | [0.0](/filings/0001108524-26-000190.md) |
| Shareholders' equity | $bn | [58.1](/filings/0001108524-24-000034.md) | [59.6](/filings/0001108524-26-000060.md) | [59.7](/filings/0001108524-25-000238.md) | [57.6](/filings/0001108524-25-000238.md) | [58.5](/filings/0001108524-25-000238.md) | [61.2](/filings/0001108524-26-000190.md) | [60.7](/filings/0001108524-26-000190.md) | [61.3](/filings/0001108524-26-000190.md) | [60.0](/filings/0001108524-25-000238.md) | [59.1](/filings/0001108524-26-000190.md) | [34.2](/filings/0001108524-26-000190.md) | [38.4](/filings/0001108524-26-000190.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $bn | [1.5](/filings/0001108524-24-000034.md) | [3.4 d](/filings/0001108524-26-000060.md) | [6.2](/filings/0001108524-25-000030.md) | [0.9](/filings/0001108524-25-000088.md) | [2.0](/filings/0001108524-25-000238.md) | [4.0 d](/filings/0001108524-26-000060.md) | [6.5](/filings/0001108524-26-000127.md) | [0.7](/filings/0001108524-26-000190.md) | [2.3](/filings/0001108524-25-000238.md) | [5.5 d](/filings/0001108524-26-000060.md) | [6.7](/filings/0001108524-26-000127.md) | [1.3](/filings/0001108524-26-000190.md) |
| Capital expenditure | $bn | [0.2](/filings/0001108524-24-000034.md) | [0.1 d](/filings/0001108524-26-000060.md) | [0.2](/filings/0001108524-25-000030.md) | [0.1](/filings/0001108524-25-000088.md) | [0.2](/filings/0001108524-25-000238.md) | [0.2 d](/filings/0001108524-26-000060.md) | [0.2](/filings/0001108524-26-000127.md) | [0.1](/filings/0001108524-26-000190.md) | [0.1](/filings/0001108524-25-000238.md) | [0.1 d](/filings/0001108524-26-000060.md) | [0.1](/filings/0001108524-26-000127.md) | [0.2](/filings/0001108524-26-000190.md) |
| Dividends paid | $bn | [0.0](/filings/0001108524-24-000034.md) | [0.0 d](/filings/0001108524-26-000060.md) | [0.4](/filings/0001108524-25-000030.md) | [0.4](/filings/0001108524-25-000088.md) | [0.4](/filings/0001108524-25-000238.md) | [0.4 d](/filings/0001108524-26-000060.md) | [0.4](/filings/0001108524-26-000127.md) | [0.4](/filings/0001108524-26-000190.md) | [0.4](/filings/0001108524-25-000238.md) | [0.4 d](/filings/0001108524-26-000060.md) | [0.4](/filings/0001108524-26-000127.md) | [0.4](/filings/0001108524-26-000190.md) |
| Share repurchases | $bn | [1.9](/filings/0001108524-24-000034.md) | [1.7 d](/filings/0001108524-26-000060.md) | [2.1](/filings/0001108524-25-000030.md) | [4.3](/filings/0001108524-25-000088.md) | [1.3](/filings/0001108524-25-000238.md) | [0.1 d](/filings/0001108524-26-000060.md) | [2.6](/filings/0001108524-26-000127.md) | [2.2](/filings/0001108524-26-000190.md) | [3.8](/filings/0001108524-25-000238.md) | [3.9 d](/filings/0001108524-26-000060.md) | [27.2](/filings/0001108524-26-000127.md) | [0.1](/filings/0001108524-26-000190.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,000](/filings/0001108524-23-000048.md) | [988](/filings/0001108524-24-000009.md) | [986](/filings/0001108524-24-000022.md) | [981](/filings/0001108524-24-000034.md) | [985](/filings/0001108524-25-000030.md) | [973](/filings/0001108524-25-000088.md) | [965](/filings/0001108524-25-000238.md) | [970](/filings/0001108524-26-000127.md) | [962](/filings/0001108524-26-000190.md) | [952](/filings/0001108524-25-000238.md) | [871](/filings/0001108524-26-000127.md) | [821](/filings/0001108524-26-000190.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 823,000,000 at 2026-08-20, from the cover of the [10-Q filed 2026-08-27](/filings/0001108524-26-000190.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.